Pricing Log in Create free account

IN8bio, Inc. (INAB) vs Pluri Inc. (PLUR)

IN8bio, Inc. and Pluri Inc. are both Biotechnology companies. IN8bio, Inc. and Pluri Inc. are of similar size ($11.9M and $11.7M). IN8bio, Inc. has the higher net margin (0.00% vs −2,344.6%) and the lower return on invested capital (−2,948.6% vs −526.9%). Across the 13 metrics below, IN8bio, Inc. leads on 7 and Pluri Inc. on 6.

Valuation

Metric INAB PLUR Biotechnology median
P/E n/m n/m 8.50
P/S n/m 8.92 9.71
P/B 1.18 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 28.99 9.21
Earnings yield (145.95%) (263.44%) (33.15%)
Free cash flow yield (67.71%) (222.94%) (25.50%)

Profitability

Metric INAB PLUR Biotechnology median
Gross margin 0.00% 44.59% 65.16%
Operating margin 0.00% (2,454.53%) 0.00%
Net margin 0.00% (2,344.59%) 0.00%
Free cash flow margin 0.00% (1,988.48%) 0.00%
Return on equity (111.11%) 260.35% (56.36%)
Return on assets (90.80%) (74.95%) (48.04%)
Return on invested capital (2,948.56%) (526.92%) 0.00%

Growth

Metric INAB PLUR Biotechnology median
Revenue growth (TTM) — (23.95%) 6.02%
EPS growth (last fiscal year) 74.06% 31.46% 30.26%
Revenue growth, 5-year CAGR — 113.32% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INAB PLUR Biotechnology median
Debt to equity 0.00 (1.62) 0.00
Current ratio 8.21 0.27 4.72
Net debt to EBITDA 1.56 (0.83) 0.96

Dividend

Metric INAB PLUR Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric INAB PLUR Biotechnology median
Market cap 11.68m 11.86m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack